$ISRG

2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG

Intuitive Surgical (ISRG) and Elevance Health (ELV) reported Q3 earnings that exceeded expectations. ISRG reported $3.00 EPS and $3.05B revenue, with 22% revenue growth. ELV reported $6.99 EPS and $50.4B revenue, with a 50% EPS beat. Both companies raised guidance and showed strong growth metrics.

Original reporting
Published Oct 21, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG — source image
Decision brief

The 30-second read

$ISRGBullishHigh
01

Why it matters

Both companies delivered material earnings surprises and raised guidance, likely prompting short‑term buying interest.

02

Market read

Fresh earnings beats for two sizable health‑care stocks provide actionable trading ideas.

03

What to watch

Elevance's dividend yield is modest and its growth relies on cost‑management, which may be vulnerable to policy changes.

Relevance 8/10Novelty 9/10Timing: post‑market today

Background

The article summarizes Q3 earnings beats for two large U.S. healthcare companies, providing key financial metrics and guidance updates.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Intuitive Surgical reported Q3 earnings of $3.00 EPS beating estimates by 15% and raised FY26 guidance, a fresh earnings beat for a large‑cap med‑tech company.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

The beat is sizable, guidance is raised, and the company has a strong growth narrative.

$ELVBullishHigh confidence
Context

Elevance Health posted Q3 adjusted EPS of $6.99, 50% above estimates, and lifted FY26 EPS guidance to at least $29, a fresh earnings beat for a major health insurer.

Expected impact

upward pressure as the market absorbs the strong profit beat and guidance raise

Evidence & confidence

The beat is large, guidance is increased, and the insurer shows improving margins.

Market effects

Both results reinforce optimism for the broader healthcare and medical‑technology sectors.

U.S. healthcare equities may see a modest lift.

Limited to investors focused on U.S. health‑care stocks.

Counterpoint

The settlement cost and competitive pressures on Intuitive Surgical could temper upside.

Key entities

  • Intuitive Surgical

    Robotic‑surgery equipment maker (ticker ISRG).

  • Elevance Health

    Health‑insurance provider (ticker ELV).

Related articles

$ISRGMedAI 8/10

Intuitive Surgical Sinks 6% as U.S. da Vinci Growth Slows to “Lowest We’ve Seen Since COVID”

Intuitive Surgical (ISRG) shares dropped 6% after reporting Q3 revenue of $3.05B, adjusted EPS of $3.00, and U.S. da Vinci procedure growth of 10%, the lowest since COVID. The company narrowed its 2026 procedure growth outlook and took a $450M antitrust charge. Management plans to cut instrument and accessory revenue per procedure by 3%-5% to boost volume.

Med

Elevance Earns $1.4 Billion Quarterly Profit as Membership Falls by 487,000 and Insurer Calls 2026 the Medicaid Trough

Elevance Health reported a $1.4B Q3 profit, up from $1.2B a year earlier, with 44.9M members, down 487K. The company expects 2026 to be the low point for Medicaid margins, with improvement in 2027. Elevance raised its full-year outlook to at least $29 per share, but is exiting some Medicaid markets and tightening spending. Medicaid work requirements begin in January 2027, potentially affecting 2.3M people.

$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.